## Drug Monograph

| | |
|---|---|
| Drug/Drug Class: | **Noctiva™ (desmopressin acetate) nasal spray /Vasopressin Analog** |
| Prepared for: | MO HealthNet |
| Prepared by: | Conduent |

☒ **New Criteria** ☐ **Revision of Existing Criteria**

## Executive Summary

| | |
|---|---|
| **Purpose:** | The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use. |
| **Dosage Forms:** | Noctiva™ is available as a preservative free nasal spray that delivers 0.1 ml of Noctiva™. Each spray of the 0.83 mcg/0.1 ml strength of desmopressin acetate contains 0.83 mcg of desmopressin acetate (equivalent to 0.75 mcg of desmopressin). Each spray of the 1.66 mcg/0.1 ml strength of desmopressin acetate contains 1.66 mcg of desmopressin acetate (equivalent to 1.5 mcg of desmopressin). |
| **Manufacturer:** | Manufactured for: Avadel Specialty Pharmaceuticals, LLC., Chesterfield, MO 63005 |
| **Indications:** | Noctiva™ is indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. |
| **Costs:** | $424.99 per bottle of each strength of Noctiva™. Wholesale Acquisition Cost |
| **Summary of Findings:** | The MO HealthNet Division recommends prior authorization status for this product. |
| **Status Recommendation:** | ☒ Prior Authorization (PA) Required ☐ Open Access<br>☐ Fiscal Edit ☐ PDL |
| **Type of PA Criteria:** | ☐ Increased Risk of ADE ☐ Preferred<br>☒ Appropriate Indications ☐ No PA Required |

Prepared By: Luke Boehmer PharmD
Date: August 17, 2018

© 2018 Conduent Business Services, LLC All Rights Reserved.